γ-Diisopropylamino-buttersaeure-methylester | 92147-84-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: γ-Diisopropylamino-buttersaeure-methylester
• 英文别名: 4-Diisopropylamino-buttersaeure-methylester；Methyl 4-(dipropan-2-ylamino)butanoate；methyl 4-[di(propan-2-yl)amino]butanoate
• CAS: 92147-84-7
• 化学式: C₁₁H₂₃NO₂
• 分子量: 201.309
• InChiKey: LUHUYGWMFMHRHE-UHFFFAOYSA-N

物化性质

• 沸点：
  66-70 °C(Press: 1 Torr)
• 密度：
  0.908±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  14
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.91
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  γ-Diisopropylamino-buttersaeure-methylester 在 盐酸 作用下， 生成 γ-Diisopropylamino-buttersaeure
  参考文献：
  名称：

  Intramolecular Assistance of Decarboxylative Acylation

  摘要：

  DOI：

  10.1021/ja01474a024
• 作为产物：
  描述：

  4-碘丁酸甲酯 、 二异丙胺 以 苯 为溶剂， 生成 γ-Diisopropylamino-buttersaeure-methylester
  参考文献：
  名称：

  Intramolecular Assistance of Decarboxylative Acylation

  摘要：

  DOI：

  10.1021/ja01474a024

文献信息

• [EN] LIPID NANOPARTICLE FORMULATIONS<br/>[FR] FORMULATIONS DE NANOPARTICULES LIPIDIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2018081480A1

  公开（公告）日：2018-05-03

  Improved formulations of lipid nanoparticles are provided. Use of the lipid nanoparticles for delivery of a therapeutic agent and methods for their preparation are also provided.

  提供了改进的脂质纳米粒子配方。还提供了利用这些脂质纳米粒子传递治疗剂的方法以及它们的制备方法。
• [EN] LIPIDS AND LIPID NANOPARTICLE FORMULATIONS FOR DELIVERY OF NUCLEIC ACIDS<br/>[FR] LIPIDES ET FORMULATIONS DE NANOPARTICULES DE LIPIDES POUR LA LIBÉRATION D'ACIDES NUCLÉIQUES
  申请人：ACUITAS THERAPEUTICS INC

  公开号：WO2017117528A1

  公开（公告）日：2017-07-06

  Compounds are provided having the following structure (I) or (II): or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R, R1, R2, L, X, L, G1, G2, Z, a1, a2 and n are independently as defined herein for each of structures (I) and (II). Use of the compounds as a component of lipid nanoparticle formulations for delivery of a therapeutic agent, compositions comprising the compounds and methods for their use and preparation are also provided.

  提供具有以下结构（I）或（II）的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中R、R1、R2、L、X、L、G1、G2、Z、a1、a2和n分别如本文所定义的用于结构（I）和（II）。还提供了将这些化合物用作脂质纳米粒子配方的组分以传递治疗剂、包含这些化合物的组合物以及其使用和制备方法。
• [EN] CIRCULAR RNA COMPOSITIONS AND METHODS<br/>[FR] MÉTHODES ET COMPOSITIONS D'ARN CIRCULAIRE
  申请人：ORNA THERAPEUTICS INC

  公开号：WO2021189059A2

  公开（公告）日：2021-09-23

  Circular RNA, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises post splicing group I in iron fragments, spacers, an IRES, optional duplex forming regions, and more than one expression sequence. In some embodiments, the expression sequences are separated by one or more polynucleotide sequences encoding a cleavage site. In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
• [EN] CIRCULAR RNA COMPOSITIONS AND METHODS<br/>[FR] COMPOSITIONS D'ARN CIRCULAIRE ET MÉTHODES
  申请人：ORNA THERAPEUTICS INC

  公开号：WO2021226597A2

  公开（公告）日：2021-11-11

  Disclosed herein are circular RNAs and transfer vehicles, along with related compositions and methods of treatment. The circular RNAs can comprise group I intron fragments, spacers, an IRES, duplex forming regions, and/or an expression sequence, thereby having the features of improved expression, functional stability, low immunogenicity, ease of manufacturing, and/or extended half-life compared to linear RNA. Pharmaceutical compositions comprising such circular RNAs and transfer vehicles are particularly suitable for efficient protein expression in immune cells in vivo. Also disclosed are precursor RNAs and materials useful in producing the precursor or circular RNAs, which have improved circularization efficiency and/or are compatible with effective circular RNA purification methods.